 |
 |
|
|
RESÚMENES ABRIL 2007 |
Psychotic Disorders
& Antipsychotics
(Haga un click en la
información del journal para acceder al resúmen)
Metabolic control
in patients with schizophrenia treated with amisulpride
or olanzapine
Peuskens, Joseph; De Hert, Marc;
Mortimer, Ann; for the SOLIANOL Study Group
International Clinical Psychopharmacology. 22(3):145-152, May 2007
Olanzapine overdose: a
series of analytically confirmed cases
Morgan, Mary; Peter Hackett,
L; Isbister, Geoffrey K
International Clinical
Psychopharmacology. 22(3):183-186,
May 2007
A 6-month prospective, observational,
naturalistic, uncontrolled study to evaluate the effectiveness and tolerability
of oral ziprasidone in patients with schizophrenia
C. Arango, M. Gómez-Beneyto, J. Brenlla, C. Gastó, F. Sarramea-Crespo, L. Chamorro, X. Masramon,
T. Díez and on behalf of the ZIS Study Group
European Neuropsychopharmacology. Volume 17, Issues 6-7, May-June 2007, Pages 456-463
A significant correlation between ward
temperature and the severity of symptoms in schizophrenia inpatients — A
longitudinal study
Roni Shiloh, Hanan Munitz, Rafael Stryjer and Abraham Weizman
European Neuropsychopharmacology. Volume 17, Issues 6-7, May-June 2007, Pages 478-482
Effects of acute antipsychotic treatment on
brain activation in first episode psychosis: An fMRI
study
P. Fusar-Poli, M.R. Broome, P. Matthiasson,
S.C.R. Williams, M. Brammer and P.K. McGuire
European Neuropsychopharmacology. Volume 17, Issues 6-7, May-June 2007, Pages 492-500
Neuroprotection:
A Therapeutic Strategy to Prevent Deterioration Associated with Schizophrenia
Jeffrey A.
Lieberman, Diana O. Perkins, and L. Fredrik Jarskog
CNS Spectr.
12:3(Suppl 4):1-16
TEXTO GRATUITO
Premorbid IQ varies across different definitions of
schizophrenia
ANNICK URFER PARNAS,
LENNART JANSSON, PETER HANDEST, JAN NIELSEN, DITTE SÆBYE, and JOSEF PARNAS
World Psychiatry. 2007 February; 6(1): 38–41
TEXTO GRATUITO
Psychosis
risk as a function of age at onset. A comparison between early-
and late-onset psychosis in a general population
sample
Sebastian Köhler,
Jim van Os, Ron de Graaf,
Wilma Vollebergh, Frans Verhey and Lydia Krabbendam
Social Psychiatry and Psychiatric Epidemiology. Volume 42, Number 4 / May, 2007: 288-294
Forty-two-years
later: the outcome of childhood-onset schizophrenia
H. Remschmidt,
M. Martin, C. Fleischhaker, F. M. Theisen, K. Hennighausen,
C. Gutenbrunner and E. Schulz
Journal of Neural Transmission. Volume 114, Number 4 / April, 2007: 505-512
Characteristics and Use
Patterns of Patients Taking First-Generation Depot Antipsychotics
or Oral Antipsychotics for Schizophrenia
Lizheng
Shi, Haya Ascher-Svanum, Baojin Zhu, Douglas Faries,
William Montgomery, and Stephen R. Marder
Psychiatr Serv 58:482-488, April 2007
Long-Term Antipsychotic Polypharmacy in the VA Health System: Patient
Characteristics and Treatment Patterns
Julie
A. Kreyenbuhl, Marcia Valenstein,
John F. McCarthy, Dara Ganoczy,
and Frederic C. Blow
Psychiatr
Serv 58:489-495, April 2007
Outcomes of Obese, Clozapine-Treated Inpatients With
Schizophrenia Placed on a Six-Month Diet and Physical Activity Program
Mei-Kuei
Wu, Chin-Kun Wang, Ya-Mei Bai,
Chih-Yang Huang, and Shin-Da
Lee
Psychiatr
Serv 58:544-550, April 2007
Neurofunctional correlates of vulnerability to psychosis: A
systematic review and meta-analysis
Paolo Fusar-Poli, Jorge Perez, Matthew Broome, Stefan Borgwardt, Anna Placentino,
Eduardo Caverzasi, Mariachiara
Cortesi, Pierangelo Veggiotti, Peirluigi Politi, Francesco Barale and
Philip McGuire
Neuroscience & Biobehavioral
Reviews. Volume 31, Issue 4, 2007,
Pages 465-484
Predictors of acute treatment response in
patients with a first episode of non-affective psychosis: Sociodemographics,
premorbid and clinical variables
Benedicto Crespo-Facorro, José María
Pelayo-Terán, Rocío Pérez-Iglesias, MariLuz Ramírez-Bonilla, Obdulia Martínez-García, Gema Pardo-García and José Luis Vázquez-Barquero
Journal of Psychiatric Research. Volume 41, Issue 8, October 2007, Pages 659-666
Therapeutic drug monitoring for optimizing amisulpride therapy in patients with Schizophrenia
Matthias J. Müller, Boris Regenbogen,
Sebastian Härtter, Franz X. Eich
and Christoph Hiemke
Journal of Psychiatric Research. Volume 41, Issue 8, October 2007, Pages 673-679
Elevated Hemoglobin A1c as a Possible Indicator of Diabetes Mellitus and
Diabetic Ketoacidosis in Schizophrenia Patients
Receiving Atypical Antipsychotics
David C. Henderson, Enrico
Cagliero, Paul M. Copeland, Pearl M. Louie, Christina
P. Borba, Xiaoduo Fan,
Oliver Freudenreich, and Donald C. Goff
J Clin Psychiatry 2007;68:533-541
Quetiapine
and Long-Term Weight Change: A Comprehensive Data Review of Patients With Schizophrenia
Martin Brecher, Ronald
W. Leong, Göran Stening, Lisa Osterling-Koskinen, and A. Martin Jones
J Clin Psychiatry 2007;68:597-603
Selective Serotonin Reuptake
Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of Schizophrenia: A
Meta-Analysis
Amir Ali Sepehry, Stéphane
Potvin, Robert Élie, and Emmanuel
Stip
J Clin Psychiatry 2007;68:604-610
Neurological Soft Signs in
Schizophrenia Patients With Obsessive-Compulsive
Disorder
Michael
Poyurovsky, Sarit Faragian, Artashes Pashinian, Aya Levi, Alexander Viosburd, Raphael Stryjer, Ronit Weizman, Camil Fuchs, and Abraham Weizman
J
Neuropsychiatry Clin Neurosci 19:145-150, May 2007
The effect of clozapine
on adverse incidents in a low-secure challenging behaviour
unit
M Dominic
Beer, Al Aditya Khan and Kalaanithi Ratnajothy
Journal
of Psychiatric Intensive Care (2006), 2: 65-70
Psychotic experiences in the
general population: A twenty-year prospective community study
Wulf Rössler, Anita Riecher-Rössler,
Jules Angst, Robin Murray, Alex Gamma, Dominque Eich, Jim van Os and Vladeta Ajdacic Gross
Schizophrenia Research. Volume 92, Issues 1-3,
May 2007, Pages 1-14
Correlates of hallucinations
in schizophrenia: A cross-cultural evaluation
P. Thomas, P. Mathur, I.I. Gottesman, R. Nagpal, V.L. Nimgaonkar and S.N. Deshpande
Schizophrenia Research. Volume 92, Issues 1-3,
May 2007, Pages 41-49
Premorbid
adjustment in schizophrenia — An important aspect of
phenotype definition
Christine Schmael, Alexander Georgi,
Bertram Krumm, Christin Buerger, Monika Deschner, Markus
M. Nöthen, Thomas G. Schulze and Marcella Rietschel
Schizophrenia Research. Volume 92, Issues 1-3,
May 2007, Pages 50-62
Remission criteria for
schizophrenia: Evaluation in a large naturalistic cohort
Marc De Hert, Ruud van Winkel, Martien Wampers, John Kane, Jim van Os and Joseph Peuskens
Schizophrenia Research. Volume 92, Issues 1-3, May 2007, Pages 68-73
Risperidone
augmentation for schizophrenia partially responsive to clozapine:
A double-blind, placebo-controlled trial
Oliver Freudenreich, David C. Henderson, Jared P. Walsh, Melissa
A. Culhane and Donald C. Goff
Schizophrenia Research. Volume 92, Issues 1-3,
May 2007, Pages 90-94
A clinical study of the
association of antipsychotics with hyperlipidemia
Jose de Leon,
Margaret T. Susce, Maria Johnson, Mike Hardin, Lana
Pointer, Gualberto Ruaño,
Andreas Windemuth and Francisco J. Diaz
Schizophrenia Research. Volume 92, Issues 1-3,
May 2007, Pages 95-102
Low-density lipoprotein
cholesterol in patients treated with atypical antipsychotics:
Missed targets and lost opportunities
Schizophrenia Research. Volume 92, Issues 1-3,
May 2007, Pages 103-107
Risperidone
significantly inhibits interferon-γ-induced microglial
activation in vitro
Takahiro Kato,
Akira Monji, Sadayuki Hashioka and Shigenobu Kanba
Schizophrenia Research. Volume 92, Issues 1-3,
May 2007, Pages 108-115
Neurocognitive
indicators for a conversion to psychosis: Comparison of patients in a
potentially initial prodromal state who did or did
not convert to a psychosis
Ralf Pukrop, Stephan Ruhrmann, Frauke Schultze-Lutter, Andreas Bechdolf, Anke Brockhaus-Dumke and Joachim Klosterkötter
Schizophrenia Research. Volume 92, Issues 1-3,
May 2007, Pages 116-125
Occipital lobe gray matter
volume in male patients with chronic schizophrenia: A quantitative MRI study
Toshiaki Onitsuka, Robert W. McCarley, Noriomi Kuroki, Chandlee C.
Dickey, Marek Kubicki,
Susan S. Demeo, Melissa Frumin,
Ron Kikinis, Ferenc A. Jolesz and Martha E. Shenton
Schizophrenia Research. Volume 92, Issues 1-3,
May 2007, Pages 197-206
Effect of antipsychotics
on pituitary gland volume in treatment-naïve first-episode schizophrenia: A
pilot study
Frank P. MacMaster, Rhonda El-Sheikh, Ameet
R. Upadhyaya, Jeffrey Nutche,
David R. Rosenberg and Matcheri Keshavan
Schizophrenia Research. Volume 92, Issues 1-3,
May 2007, Pages 207-210
Internal capsule, corpus callosum and long associative fibers in good and poor
outcome schizophrenia: A diffusion tensor imaging survey
Serge A. Mitelman, Yuliya Torosjan, Randall E. Newmark,
Jason S. Schneiderman, King-Wai
Chu, Adam M. Brickman, M. Mehmet Haznedar,
Erin A. Hazlett, Cheuk Y.
Tang, Lina Shihabuddin and
Monte S. Buchsbaum
Schizophrenia Research. Volume 92, Issues 1-3,
May 2007, Pages 211-224
Intellectual functioning and
memory deficits in schizophrenia
Juan Carlos Ruiz, María José Soler, Inma
Fuentes and Pilar Tomás
Comprehensive Psychiatry. Volume 48, Issue 3,
May-June 2007, Pages 276-282
Insight and psychopathology in
never-treated schizophrenia
Srinivasan Tirupati, Raman Padmavati, Rangaswamy Thara and Robin G. McCreadie
Comprehensive Psychiatry.
Volume 48, Issue 3, May-June 2007, Pages 264-268
Effectiveness, tolerability,
and safety of ziprasidone in patients with
schizophrenia or schizoaffective disorder: Results of a multi-centre
observational trial
Duerten Kudla, Martin Lambert, Sabine
Domin, Siegfried Kasper and Dieter Naber
European Psychiatry. Volume 22, Issue 3, April
2007, Pages 195-202
The effect of atypical versus typical antipsychotics on tardive dyskinesia. A
naturalistic study
Jose de Leon